Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 19 de 19
Filtrar
1.
Nutrients ; 16(4)2024 Feb 11.
Artículo en Inglés | MEDLINE | ID: mdl-38398832

RESUMEN

Targeting mitochondrial function is a promising approach to prevent metabolic dysfunction-associated steatotic liver disease (MASLD). Cardiolipin (CL) is a unique lipid comprising four fatty acyl chains localized in the mitochondrial inner membrane. CL is a crucial phospholipid in mitochondrial function, and MASLD exhibits CL-related anomalies. Kaempferol (KMP), a natural flavonoid, has hepatoprotective and mitochondrial function-improving effects; however, its influence on CL metabolism in fatty liver conditions is unknown. In this study, we investigated the effects of KMP on mitochondrial function, focusing on CL metabolism in a fatty liver cell model (linoleic-acid-loaded C3A cell). KMP promoted mitochondrial respiratory functions such as ATP production, basal respiration, and proton leak. KMP also increased the gene expression levels of CPT1A and PPARGC1A, which are involved in mitochondrial ß-oxidation. Comprehensive quantification of CL species and related molecules via liquid chromatography/mass spectrometry showed that KMP increased not only total CL content but also CL72:8, which strongly favors ATP production. Furthermore, KMP improved the monolysocardiolipin (MLCL)/CL ratio, an indicator of mitochondrial function. Our results suggest that KMP promotes energy production in a fatty liver cell model, associated with improvement in mitochondrial CL profile, and can serve as a potential nutrition factor in preventing MASLD.


Asunto(s)
Cardiolipinas , Hígado Graso , Humanos , Cardiolipinas/metabolismo , Quempferoles/farmacología , Hígado Graso/metabolismo , Hepatocitos/metabolismo , Adenosina Trifosfato
2.
Int J Mol Sci ; 24(12)2023 Jun 13.
Artículo en Inglés | MEDLINE | ID: mdl-37373208

RESUMEN

The kidney contains numerous mitochondria in proximal tubular cells that provide energy for tubular secretion and reabsorption. Mitochondrial injury and consequent excessive reactive oxygen species (ROS) production can cause tubular damage and play a major role in the pathogenesis of kidney diseases, including diabetic nephropathy. Accordingly, bioactive compounds that protect the renal tubular mitochondria from ROS are desirable. Here, we aimed to report 3,5-dihydroxy-4-methoxybenzyl alcohol (DHMBA), isolated from the Pacific oyster (Crassostrea gigas) as a potentially useful compound. In human renal tubular HK-2 cells, DHMBA significantly mitigated the cytotoxicity induced by the ROS inducer L-buthionine-(S, R)-sulfoximine (BSO). DHMBA reduced the mitochondrial ROS production and subsequently regulated mitochondrial homeostasis, including mitochondrial biogenesis, fusion/fission balance, and mitophagy; DHMBA also enhanced mitochondrial respiration in BSO-treated cells. These findings highlight the potential of DHMBA to protect renal tubular mitochondrial function against oxidative stress.


Asunto(s)
Antioxidantes , Crassostrea , Animales , Humanos , Antioxidantes/farmacología , Antioxidantes/metabolismo , Especies Reactivas de Oxígeno/metabolismo , Estrés Oxidativo , Túbulos Renales , Etanol/metabolismo , Mitocondrias/metabolismo
3.
Nutrients ; 14(22)2022 Nov 10.
Artículo en Inglés | MEDLINE | ID: mdl-36432448

RESUMEN

Late-onset hypogonadism, a male age-related syndrome characterized by a decline in testosterone production in the testes, is commonly treated with testosterone replacement therapy, which has adverse side effects. Therefore, an alternative treatment is highly sought. Supplementation of a high dosage of biotin, a water-soluble vitamin that functions as a coenzyme for carboxylases involved in carbohydrate, lipid, and amino acid metabolism, has been shown to influence testis functions. However, the involvement of biotin in testis steroidogenesis has not been well clarified. In this study, we examined the effect of biotin on testosterone levels in mice and testis-derived cells. In mice, intraperitoneal treatment with biotin (1.5 mg/kg body weight) enhanced testosterone levels in the serum and testes, without elevating serum levels of pituitary luteinizing hormone. To investigate the mechanism in which biotin increased the testosterone level, mice testis-derived I-10 cells were used. The cells treated with biotin increased testosterone production in a dose- and time-dependent manner. Biotin treatment elevated intracellular cyclic adenosine monophosphate levels via adenylate cyclase activation, followed by the activation of protein kinase A and testosterone production. These results suggest that biotin may have the potential to improve age-related male syndromes associated with declining testosterone production.


Asunto(s)
Testículo , Testosterona , Ratones , Masculino , Animales , Biotina/farmacología , Hormona Luteinizante/metabolismo , Proteínas Quinasas Dependientes de AMP Cíclico/metabolismo
4.
Cells ; 12(1)2022 12 25.
Artículo en Inglés | MEDLINE | ID: mdl-36611880

RESUMEN

The kidney contains many mitochondria that generate ATP to provide energy for cellular processes. Oxidative stress injury can be caused by impaired mitochondria with excessive levels of reactive oxygen species. Accumulating evidence has indicated a relationship between oxidative stress and kidney diseases, and revealed new insights into mitochondria-targeted therapeutics for renal injury. Improving mitochondrial homeostasis, increasing mitochondrial biogenesis, and balancing mitochondrial turnover has the potential to protect renal function against oxidative stress. Although there are some reviews that addressed this issue, the articles summarizing the relationship between mitochondria-targeted effects and the risk factors of renal failure are still few. In this review, we integrate recent studies on oxidative stress and mitochondrial function in kidney diseases, especially chronic kidney disease. We organized the causes and risk factors of oxidative stress in the kidneys based in their mitochondria-targeted effects. This review also listed the possible candidates for clinical therapeutics of kidney diseases by modulating mitochondrial function.


Asunto(s)
Estrés Oxidativo , Insuficiencia Renal Crónica , Humanos , Especies Reactivas de Oxígeno/metabolismo , Riñón/metabolismo , Mitocondrias/metabolismo , Insuficiencia Renal Crónica/metabolismo
5.
Physiol Rep ; 9(24): e15092, 2021 12.
Artículo en Inglés | MEDLINE | ID: mdl-34921520

RESUMEN

Sodium-dependent glucose cotransporters (SGLTs) have attracted considerable attention as new targets for type 2 diabetes mellitus. In the kidney, SGLT2 is the major glucose uptake transporter in the proximal tubules, and inhibition of SGLT2 in the proximal tubules shows renoprotective effects. On the other hand, SGLT1 plays a role in glucose absorption from the gastrointestinal tract, and the relationship between SGLT1 inhibition in the gut and renal function remains unclear. Here, we examined the effect of SGL5213, a novel and potent intestinal SGLT1 inhibitor, in a renal failure (RF) model. SGL5213 improved renal function and reduced gut-derived uremic toxins (phenyl sulfate and trimethylamine-N-oxide) in an adenine-induced RF model. Histological analysis revealed that SGL5213 ameliorated renal fibrosis and inflammation. SGL5213 also reduced gut inflammation and fibrosis in the ileum, which is a primary target of SGL5213. Examination of the gut microbiota community revealed that the Firmicutes/Bacteroidetes ratio, which suggests gut dysbiosis, was increased in RF and SGL5213 rebalanced the ratio by increasing Bacteroidetes and reducing Firmicutes. At the genus level, Allobaculum (a major component of Erysipelotrichaceae) was significantly increased in the RF group, and this increase was canceled by SGL5213. We also measured the effect of SGL5213 on bacterial phenol-producing enzymes that catalyze tyrosine into phenol, following the reduction of phenyl sulfate, which is a novel marker and a therapeutic target for diabetic kidney disease DKD. We found that the enzyme inhibition was less potent, suggesting that the change in the microbial community and the reduction of uremic toxins may be related to the renoprotective effect of SGL5213. Because SGL5213 is a low-absorbable SGLT1 inhibitor, these data suggest that the gastrointestinal inhibition of SGLT1 is also a target for chronic kidney diseases.


Asunto(s)
Adenina/toxicidad , Microbioma Gastrointestinal/efectos de los fármacos , Insuficiencia Renal/inducido químicamente , Insuficiencia Renal/tratamiento farmacológico , Transportador 1 de Sodio-Glucosa/antagonistas & inhibidores , Sorbitol/análogos & derivados , Animales , Glucemia/efectos de los fármacos , Glucemia/metabolismo , Microbioma Gastrointestinal/fisiología , Ratones , Ratones Endogámicos C57BL , Insuficiencia Renal/metabolismo , Sorbitol/farmacología , Sorbitol/uso terapéutico
6.
Molecules ; 25(20)2020 Oct 14.
Artículo en Inglés | MEDLINE | ID: mdl-33066465

RESUMEN

Testosterone plays an important role in male sexual characteristics and maturation, and decreased testosterone levels increase the risk of several diseases. Recently, onion extract rich in cysteine sulfoxides, which are amino acids unique to onions, has been reported to alleviate age-related symptoms resulting from decreased testosterone levels in males. However, the mechanism underlying the suppression of low testosterone levels by cysteine sulfoxides has not been elucidated. In this study, we found that onion extract containing cysteine sulfoxides enhanced progesterone, a precursor of testosterone, in mouse testis-derived I-10 tumor cells. Furthermore, cysteine sulfoxides activated protein kinase A (PKA) and cyclic adenosine monophosphate response element-binding protein, which are key factors in steroidogenesis. These results suggest that cysteine sulfoxides enhance steroid hormone production via activation of the PKA signaling pathway.


Asunto(s)
Proteínas Quinasas Dependientes de AMP Cíclico/metabolismo , Cisteína/análogos & derivados , Progesterona/metabolismo , Neoplasias Testiculares/patología , Animales , Línea Celular Tumoral , Proteína de Unión a Elemento de Respuesta al AMP Cíclico/metabolismo , Cisteína/química , Cisteína/farmacología , Masculino , Ratones , Cebollas/química , Ácidos Pipecólicos/farmacología , Extractos Vegetales/química , Extractos Vegetales/farmacología , Transducción de Señal , Neoplasias Testiculares/tratamiento farmacológico , Neoplasias Testiculares/metabolismo
7.
Nutrients ; 12(8)2020 Aug 18.
Artículo en Inglés | MEDLINE | ID: mdl-32824773

RESUMEN

Type 2 diabetes mellitus is a chronic disease that is characterized by hyperglycemia, insulin resistance, and dysfunctional insulin secretion. Glycemic control remains a crucial contributor to the progression of type 2 diabetes mellitus as well as the prevention or delay in the onset of diabetes-related complications. Vitamin K is a fat-soluble vitamin that plays an important role in the regulation of the glycemic status. Supplementation of vitamin K may reduce the risk of diabetes mellitus and improve insulin sensitivity. This mini-review summarizes the recent insights into the beneficial effects of vitamin K and its possible mechanism of action on insulin sensitivity and glycemic status, thereby suppressing the progression of diabetes mellitus.


Asunto(s)
Complicaciones de la Diabetes/prevención & control , Diabetes Mellitus Tipo 2 , Suplementos Dietéticos , Control Glucémico , Estado Nutricional , Vitamina K , Adulto , Anciano , Diabetes Mellitus Tipo 2/metabolismo , Diabetes Mellitus Tipo 2/prevención & control , Progresión de la Enfermedad , Femenino , Humanos , Resistencia a la Insulina , Masculino , Persona de Mediana Edad , Vitamina K/administración & dosificación , Vitamina K/farmacología , Vitamina K/fisiología , Adulto Joven
8.
Nephrol Dial Transplant ; 35(2): 250-264, 2020 02 01.
Artículo en Inglés | MEDLINE | ID: mdl-31411705

RESUMEN

BACKGROUND: Cardiorenal syndrome is a major cause of mortality in patients with chronic kidney disease (CKD). However, the involvement of detrimental humoral mediators in the pathogenesis of cardiorenal syndrome is still controversial. Trimethylamine-N-oxide (TMAO), a hepatic metabolic product of trimethylamine generated from dietary phosphatidylcholine or carnitine derived by the gut microbiota, has been linked directly with progression of cardiovascular disease and renal dysfunction. Thus, targeting TMAO may be a novel strategy for the prevention of cardiovascular disease and chronic kidney disease. METHODS: Linaclotide, a guanylate cyclase C agonist, was administered to adenine-induced renal failure (RF) mice and changes in renal function and levels of gut-derived uremic toxins, as well as the gut microbiota community, were analyzed using metabolomic and metagenomic methods to reveal its cardiorenal effect. RESULTS: Linaclotide decreased the plasma levels of TMAO at a clinically used low dose of 10 µg/kg in the adenine-induced RF mouse model. At a high concentration of 100 µg/kg, linaclotide clearly improved renal function and reduced the levels of various uremic toxins. A reduction in TMAO levels following linaclotide treatment was also observed in a choline-fed pro-atherosclerotic model. Linaclotide ameliorated renal inflammation and fibrosis and cardiac fibrosis, as well as decreased the expression of collagen I, transforming growth factor-ß, galectin-3 (Gal-3) and ST2 genes. Plasma levels of Gal-3 and ST2 were also reduced. Because exposure of cardiomyocytes to TMAO increased fibronectin expression, these data suggest that linaclotide reduced the levels of TMAO and various uremic toxins and may result in not only renal, but also cardiac, fibrosis. F4/80-positive macrophages were abundant in small intestinal crypts in RF mice, and this increased expression was decreased by linaclotide. Reduced colonic claudin-1 levels were also restored by linaclotide, suggesting that linaclotide ameliorated the 'leaky gut' in RF mice. Metagenomic analysis revealed that the microbial order Clostridiales could be responsible for the change in TMAO levels. CONCLUSION: Linaclotide reduced TMAO and uremic toxin levels and could be a powerful tool for the prevention and control of the cardiorenal syndrome by modification of the gut-cardio-renal axis.


Asunto(s)
Adenina/toxicidad , Síndrome Cardiorrenal/tratamiento farmacológico , Microbioma Gastrointestinal/efectos de los fármacos , Guanilato Ciclasa/química , Agonistas de la Guanilato Ciclasa C/farmacología , Péptidos/farmacología , Insuficiencia Renal Crónica/tratamiento farmacológico , Animales , Síndrome Cardiorrenal/inducido químicamente , Síndrome Cardiorrenal/metabolismo , Síndrome Cardiorrenal/patología , Modelos Animales de Enfermedad , Progresión de la Enfermedad , Fibrosis/inducido químicamente , Fibrosis/tratamiento farmacológico , Fibrosis/metabolismo , Fibrosis/patología , Inflamación/inducido químicamente , Inflamación/tratamiento farmacológico , Inflamación/metabolismo , Inflamación/patología , Masculino , Ratones , Ratones Endogámicos C57BL , Insuficiencia Renal Crónica/inducido químicamente , Insuficiencia Renal Crónica/metabolismo , Insuficiencia Renal Crónica/patología
9.
Int J Mol Sci ; 20(9)2019 May 10.
Artículo en Inglés | MEDLINE | ID: mdl-31083375

RESUMEN

Geranylgeraniol (GGOH), a natural isoprenoid found in plants, has anti-inflammatory effects via inhibiting the activation of nuclear factor-kappa B (NFκB). However, its detailed mechanism has not yet been elucidated. Recent studies have revealed that isoprenoids can modulate signaling molecules in innate immune responses. We found that GGOH decreased the expression of lipopolysaccharide (LPS)-induced inflammatory genes in human macrophage-like THP-1 cells. Furthermore, we observed that the suppression of NFκB signaling proteins, in particular interleukin-1 receptor-associated kinase 1 (IRAK1) and tumor necrosis factor receptor-associated factor 6 (TRAF6), occurred in GGOH-treated cells prior to LPS stimulation, suggesting an immunomodulatory effect. These results indicate that GGOH may modulate and help prevent excessive NFκB activation that can lead to numerous diseases.


Asunto(s)
Diterpenos/farmacología , Inflamación/patología , Quinasas Asociadas a Receptores de Interleucina-1/metabolismo , Macrófagos/metabolismo , Macrófagos/patología , FN-kappa B/metabolismo , Factor 6 Asociado a Receptor de TNF/metabolismo , Animales , Línea Celular , Humanos , Inflamación/genética , Lipopolisacáridos , Macrófagos/efectos de los fármacos , Ratones , Modelos Biológicos , Fosforilación/efectos de los fármacos , Células RAW 264.7 , ARN Mensajero/genética , ARN Mensajero/metabolismo , Transducción de Señal/efectos de los fármacos , Células THP-1
10.
Int J Mol Sci ; 20(8)2019 Apr 23.
Artículo en Inglés | MEDLINE | ID: mdl-31018587

RESUMEN

Vitamin K2 is indispensable for blood coagulation and bone metabolism. Menaquinone-4 (MK-4) is the predominant homolog of vitamin K2, which is present in large amounts in the pancreas, although its function is unclear. Meanwhile, ß-cell dysfunction following insulin secretion has been found to decrease in patients with type 2 diabetes mellitus. To elucidate the physiological function of MK-4 in pancreatic ß-cells, we studied the effects of MK-4 treatment on isolated mouse pancreatic islets and rat INS-1 cells. Glucose-stimulated insulin secretion significantly increased in isolated islets and INS-1 cells treated with MK-4. It was further clarified that MK-4 enhanced cAMP levels, accompanied by the regulation of the exchange protein directly activated by the cAMP 2 (Epac2)-dependent pathway but not the protein kinase A (PKA)-dependent pathway. A novel function of MK-4 on glucose-stimulated insulin secretion was found, suggesting that MK-4 might act as a potent amplifier of the incretin effect. This study therefore presents a novel potential therapeutic approach for impaired insulinotropic effects.


Asunto(s)
Glucosa/metabolismo , Secreción de Insulina , Islotes Pancreáticos/metabolismo , Vitamina K 2/análogos & derivados , Animales , Línea Celular Tumoral , AMP Cíclico/metabolismo , Insulinoma/metabolismo , Ratones , Neoplasias Pancreáticas/metabolismo , Ratas , Transducción de Señal , Vitamina K 2/metabolismo
11.
Nat Commun ; 10(1): 1835, 2019 04 23.
Artículo en Inglés | MEDLINE | ID: mdl-31015435

RESUMEN

Diabetic kidney disease is a major cause of renal failure that urgently necessitates a breakthrough in disease management. Here we show using untargeted metabolomics that levels of phenyl sulfate, a gut microbiota-derived metabolite, increase with the progression of diabetes in rats overexpressing human uremic toxin transporter SLCO4C1 in the kidney, and are decreased in rats with limited proteinuria. In experimental models of diabetes, phenyl sulfate administration induces albuminuria and podocyte damage. In a diabetic patient cohort, phenyl sulfate levels significantly correlate with basal and predicted 2-year progression of albuminuria in patients with microalbuminuria. Inhibition of tyrosine phenol-lyase, a bacterial enzyme responsible for the synthesis of phenol from dietary tyrosine before it is metabolized into phenyl sulfate in the liver, reduces albuminuria in diabetic mice. Together, our results suggest that phenyl sulfate contributes to albuminuria and could be used as a disease marker and future therapeutic target in diabetic kidney disease.


Asunto(s)
Albuminuria/etiología , Diabetes Mellitus Experimental/complicaciones , Diabetes Mellitus Tipo 1/complicaciones , Diabetes Mellitus Tipo 2/complicaciones , Nefropatías Diabéticas/sangre , Microbioma Gastrointestinal/fisiología , Ésteres del Ácido Sulfúrico/metabolismo , Adulto , Anciano , Anciano de 80 o más Años , Albuminuria/sangre , Albuminuria/tratamiento farmacológico , Albuminuria/patología , Animales , Animales Modificados Genéticamente , Estudios de Cohortes , Diabetes Mellitus Experimental/sangre , Diabetes Mellitus Experimental/inducido químicamente , Diabetes Mellitus Experimental/orina , Diabetes Mellitus Tipo 1/sangre , Diabetes Mellitus Tipo 2/sangre , Nefropatías Diabéticas/etiología , Nefropatías Diabéticas/patología , Perros , Inhibidores Enzimáticos/farmacología , Inhibidores Enzimáticos/uso terapéutico , Femenino , Humanos , Células de Riñón Canino Madin Darby , Masculino , Metabolómica/métodos , Ratones , Ratones Endogámicos C57BL , Persona de Mediana Edad , Transportadores de Anión Orgánico/genética , Podocitos/metabolismo , Podocitos/patología , Ratas , Estreptozocina/toxicidad , Ésteres del Ácido Sulfúrico/sangre , Tirosina Fenol-Liasa/antagonistas & inhibidores , Tirosina Fenol-Liasa/metabolismo , Adulto Joven
12.
Biosci Biotechnol Biochem ; 82(6): 956-962, 2018 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-29303051

RESUMEN

Isoprenoids play widely differing roles in various physiological processes in animals and plants. Geranylgeraniol (GGOH) is an isoprenoid found in plants, and is an important metabolic derivative in the isoprenoid/cholesterol synthesis pathway. Earlier studies focused on GGOH's ability to improve the side effects of bisphosphonate therapy by regulating the mevalonate pathway. More recently, the mevalonate pathway-independent effects of GGOH have been described, including anti-inflammatory, anti-tumorigenic, and neuroprotective activities. It is noteworthy that GGOH regulates the steroidogenesis pathway in testis-derived I-10 tumor cells. Testosterone is a hormone produced via steroidogenesis in testicles and plays a role in fetal development and the male reproductive system. GGOH enhanced testosterone and progesterone (its precursor) levels in I-10 cells by activating adenylate cyclase via cAMP/PKA signaling, without altering phosphodiesterase activity. These findings highlight the potential benefits of GGOH as a therapeutic agent for low testosterone levels, such as late-onset hypogonadism in men.


Asunto(s)
Diterpenos/farmacología , Células Intersticiales del Testículo/efectos de los fármacos , Testosterona/biosíntesis , Adenilil Ciclasas/genética , Adenilil Ciclasas/metabolismo , Animales , AMP Cíclico/metabolismo , Proteínas Quinasas Dependientes de AMP Cíclico/metabolismo , Suplementos Dietéticos , Humanos , Células Intersticiales del Testículo/citología , Células Intersticiales del Testículo/metabolismo , Masculino , Ácido Mevalónico/metabolismo , Progesterona/biosíntesis , Transducción de Señal , Terpenos/farmacología , Testosterona/sangre , Testosterona/metabolismo
13.
Am J Physiol Renal Physiol ; 315(4): F824-F833, 2018 10 01.
Artículo en Inglés | MEDLINE | ID: mdl-29167170

RESUMEN

Accumulation of uremic toxins, which exert deleterious effects in chronic kidney disease, is influenced by the intestinal environment; the microbiota contributes to the production of representative uremic toxins, including p-cresyl sulfate and indoxyl sulfate. Canagliflozin is a sodium-glucose cotransporter (SGLT) 2 inhibitor, and it also exerts a modest inhibitory effect on SGLT1. The inhibition of intestinal SGLT1 can influence the gastrointestinal environment. We examined the effect of canagliflozin on the accumulation of uremic toxins in chronic kidney disease using adenine-induced renal failure mice. Two-week canagliflozin (10 mg/kg po) treatment did not influence the impaired renal function; however, it significantly reduced the plasma levels of p-cresyl sulfate and indoxyl sulfate in renal failure mice (a 75% and 26% reduction, respectively, compared with the vehicle group). Additionally, canagliflozin significantly increased cecal short-chain fatty acids in the mice, suggesting the promotion of bacterial carbohydrate fermentation in the intestine. Analysis of the cecal microbiota showed that canagliflozin significantly altered microbiota composition in the renal failure mice. These results indicate that canagliflozin exerts intestinal effects that reduce the accumulation of uremic toxins including p-cresyl sulfate. Reduction of accumulated uremic toxins by canagliflozin could provide a potential therapeutic option in chronic kidney disease.


Asunto(s)
Canagliflozina/farmacología , Microbioma Gastrointestinal/efectos de los fármacos , Insuficiencia Renal Crónica/tratamiento farmacológico , Toxinas Biológicas/sangre , Animales , Modelos Animales de Enfermedad , Tracto Gastrointestinal/efectos de los fármacos , Masculino , Ratones Endogámicos C57BL , Insuficiencia Renal Crónica/sangre , Inhibidores del Cotransportador de Sodio-Glucosa 2/farmacología , Toxinas Biológicas/farmacología , Uremia/sangre , Uremia/tratamiento farmacológico
14.
Sci Rep ; 7(1): 1884, 2017 05 15.
Artículo en Inglés | MEDLINE | ID: mdl-28507324

RESUMEN

Renal fibrosis is closely related to chronic inflammation and is under the control of epigenetic regulations. Because the signaling of transforming growth factor-ß1 (TGF-ß1) and tumor necrosis factor-α (TNF-α) play key roles in progression of renal fibrosis, dual blockade of TGF-ß1 and TNF-α is desired as its therapeutic approach. Here we screened small molecules showing anti-TNF-α activity in the compound library of indole derivatives. 11 out of 41 indole derivatives inhibited the TNF-α effect. Among them, Mitochonic Acid 35 (MA-35), 5-(3, 5-dimethoxybenzyloxy)-3-indoleacetic acid, showed the potent effect. The anti-TNF-α activity was mediated by inhibiting IκB kinase phosphorylation, which attenuated the LPS/GaIN-induced hepatic inflammation in the mice. Additionally, MA-35 concurrently showed an anti-TGF-ß1 effect by inhibiting Smad3 phosphorylation, resulting in the downregulation of TGF-ß1-induced fibrotic gene expression. In unilateral ureter obstructed mouse kidney, which is a renal fibrosis model, MA-35 attenuated renal inflammation and fibrosis with the downregulation of inflammatory cytokines and fibrotic gene expressions. Furthermore, MA-35 inhibited TGF-ß1-induced H3K4me1 histone modification of the fibrotic gene promoter, leading to a decrease in the fibrotic gene expression. MA-35 affects multiple signaling pathways involved in the fibrosis and may recover epigenetic modification; therefore, it could possibly be a novel therapeutic drug for fibrosis.


Asunto(s)
Indoles/farmacología , Enfermedades Renales/metabolismo , Enfermedades Renales/patología , Transducción de Señal/efectos de los fármacos , Factor de Crecimiento Transformador beta1/metabolismo , Factor de Necrosis Tumoral alfa/metabolismo , Animales , Línea Celular , Modelos Animales de Enfermedad , Matriz Extracelular/metabolismo , Fibrosis , Hepatitis/tratamiento farmacológico , Hepatitis/etiología , Hepatitis/metabolismo , Hepatitis/patología , Histonas/metabolismo , Humanos , Quinasa I-kappa B/metabolismo , Enfermedades Renales/tratamiento farmacológico , Enfermedades Renales/etiología , Lipopolisacáridos/efectos adversos , Masculino , Metilación , Ratones , Modelos Biológicos , Fosforilación/efectos de los fármacos , Proteína smad3/metabolismo
15.
Biosci Biotechnol Biochem ; 80(4): 791-7, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26757775

RESUMEN

Testosterone levels in men decrease with age; this decline has been linked to various diseases and can shorten life expectancy. Geranylgeraniol (GGOH) is an isoprenoid found in plants that plays an important role in several biological processes; however, its role in steroidogenesis is unknown. Here, we report that GGOH enhances the production of testosterone and its precursor progesterone in testis-derived I-10 tumor cells. GGOH induced protein kinase A (PKA) activity and increased cAMP levels and was found to regulate cAMP/PKA signaling by activating adenylate cyclase without altering phosphodiesterase activity. GGOH also stimulated mRNA and protein levels of steroidogenic acute regulatory protein, a downstream effector in the cAMP/PKA pathway. These results demonstrate that GGOH enhances steroidogenesis in testis-derived cells by modulating cAMP/PKA signaling. Our findings have potential applications for the development of therapeutics that increase testosterone levels in aging men.


Asunto(s)
Proteínas Quinasas Dependientes de AMP Cíclico/metabolismo , AMP Cíclico/metabolismo , Diterpenos/farmacología , Neoplasias Testiculares/metabolismo , Testosterona/biosíntesis , Animales , Línea Celular Tumoral , Masculino , Ratones , Fosfoproteínas/metabolismo , Progesterona/biosíntesis , Transducción de Señal , Neoplasias Testiculares/enzimología , Neoplasias Testiculares/patología , Regulación hacia Arriba/efectos de los fármacos
17.
Nutrition ; 29(11-12): 1368-73, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-24103515

RESUMEN

OBJECTIVE: Diarrhea is a leading cause of mortality in children under the age of 5 y in developing countries. To our knowledge, no other studies have investigated the management of diarrhea in the Gambia. The aim of this study was to assess maternal knowledge, attitude, and practice in the causes, prevention, and management of diarrhea in children under the age of 5 y in the Gambia. METHODS: Four hundred mothers with children who have diarrhea and are under the age of 5 y were randomly recruited. Data were collected using structured questionnaires, including demographic information, knowledge about diarrhea, attitude toward the management of diarrhea, and practice for the prevention and management of diarrhea. χ(2) and Student's t tests were used for the descriptive and quantitative analysis, respectively. Simple and multiple linear regressions were used to determine the association between the variables. A P-value < 0.05 was considered statistically significant. RESULTS: The mean of maternal knowledge (K), attitude (A), practice (P), and knowledge-attitude-practice sum (KAP) scores were 14.4, 6.3, 13.2, and 33.9, respectively. The mean of knowledge scores were significantly higher in mothers who responded positively for germs (13.4 versus 12.6) and dirty hands (13.7 versus 13.0) as causes of diarrhea. Mothers with education had significantly higher knowledge (14.7 versus 14.2) and attitude scores (6.6 versus 6.1) in management of diarrhea. However, the study found a low use rate (4%) of oral rehydration solution in practice. Multiple linear regression analysis revealed that maternal age was positively associated with practice (ß = 0.061) and KAP scores (ß = 0.102). The number of children in the family was positively correlated with attitude scores (ß = 0.408). Socioeconomic status was positively associated with attitude (ß = 0.549), practice (ß = 0.841), and KAP scores (ß = 1.887). CONCLUSIONS: The mothers have high knowledge scores in the management of diarrhea; however, use of oral rehydration solution is low among children with diarrhea under the age of 5 y in the Gambia. Higher maternal age and socioeconomic status are correlated with higher practice and KAP scores.


Asunto(s)
Diarrea/terapia , Fluidoterapia/métodos , Conocimientos, Actitudes y Práctica en Salud , Adolescente , Adulto , Preescolar , Países en Desarrollo , Diarrea/prevención & control , Femenino , Gambia , Humanos , Lactante , Persona de Mediana Edad , Madres , Clase Social , Encuestas y Cuestionarios , Adulto Joven
18.
Br J Nutr ; 109(12): 2190-8, 2013 Jun 28.
Artículo en Inglés | MEDLINE | ID: mdl-23046530

RESUMEN

The present study investigated dietary intake, glucose metabolism and sex hormones in women with polycystic ovary syndrome (PCOS). A total of forty-five women (aged 25­40 years) with PCOS and 161 control women (aged 25­43 years) with non-PCOS-related infertility were recruited. Anthropometry, glucose tolerance and sex hormones were determined and dietary intake was assessed. Women with PCOS had lower serum sex hormone-binding globulin and increased BMI, waist:hip ratio, luteinising hormone, ratio of luteinising hormone: follicle-stimulating hormone, testosterone and free androgen index (FAI). Postprandial glucose, fasting insulin and insulin resistance were elevated in women with PCOS. Women with PCOS had reduced energy and carbohydrate intake but higher fat intake. Serum sex hormone-binding globulin level was negatively associated with BMI in both groups and negatively correlated with macronutrient intake in the PCOS group with hyperandrogenism. However, FAI was positively correlated with BMI, waist circumference and glucose metabolic parameters in both groups. Therefore, women with PCOS consume lower energy and carbohydrate compared with those with non-PCOS-related infertility and macronutrient intake is only negatively associated with serum sex hormone-binding globulin level in the PCOS group with hyperandrogenism.


Asunto(s)
Dieta , Hormonas Esteroides Gonadales/sangre , Infertilidad/etiología , Resistencia a la Insulina/fisiología , Obesidad/complicaciones , Síndrome del Ovario Poliquístico/complicaciones , Adulto , Análisis de Varianza , Índice de Masa Corporal , Estudios de Casos y Controles , Femenino , Humanos , Infertilidad/sangre , Obesidad/sangre , Síndrome del Ovario Poliquístico/sangre , Síndrome del Ovario Poliquístico/metabolismo , Globulina de Unión a Hormona Sexual/análisis
19.
Mol Nutr Food Res ; 52(6): 646-54, 2008 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-18537129

RESUMEN

The aberrant regulation of the phosphoinositide 3-kinase/Akt survival signaling pathway in cancer has prompted significant interest in suppression of this pathway to treat cancer. Previous studies identified an important role for phosphoinositide 3-kinase/Akt in colon cancer progression. Lycopene, a major component in tomato, exhibited potential anti-carcinogenic activity. Consumption of tomato has been associated with reduced risk of several types of human cancer. However, the inhibitory mechanisms of lycopene on the proliferation of human colon cancer have not been studied well yet. Thus we investigated the inhibitory effects of lycopene on the Akt signaling pathway in human colon cancer HT-29 cells. Lycopene inhibited cell proliferation in human colon cancer HT-29 cells with a IC(50) value of 10 microM. Lycopene treatment suppressed Akt activation and non-phosphorylated beta-catenin protein level in human colon cancer cells. Immunocytochemical results indicated that lycopene increased the phosphorylated form of beta-catenin proteins. These effects were also associated with reduced promoter activity and protein expression of cyclin D1. Furthermore, lycopene significantly increased nuclear cyclin-dependent kinase inhibitor p27(kip)abundance and inhibited phosphorylation of the retinoblastoma tumor suppressor protein in human colon cancer cells. In conclusion, lycopene inhibited cell proliferation of human colon cancer cells via suppression of the Akt signaling pathway and downstream targeted molecules.


Asunto(s)
Carotenoides/farmacología , División Celular/efectos de los fármacos , Neoplasias del Colon/patología , Proteínas Proto-Oncogénicas c-akt/antagonistas & inhibidores , Transducción de Señal/efectos de los fármacos , Neoplasias del Colon/química , Ciclina D1/genética , Expresión Génica/efectos de los fármacos , Células HT29 , Humanos , Licopeno , Fosfatidilinositol 3-Quinasas/fisiología , Inhibidores de las Quinasa Fosfoinosítidos-3 , Fosforilación , Regiones Promotoras Genéticas/efectos de los fármacos , Proteínas Proto-Oncogénicas c-akt/efectos de los fármacos , Proteínas Proto-Oncogénicas c-akt/fisiología , beta Catenina/análisis
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA